Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer.

Scientific reports - 22 Nov 2021

Lucchetti Donatella, Zurlo Ina Valeria, Colella Filomena, Ricciardi-Tenore Claudio, Di Salvatore Mariantonietta, Tortora Giampaolo, De Maria Ruggero, Giuliante Felice, Cassano Alessandra, Basso Michele, Crucitti Antonio, Laurenzana Ilaria, Artemi Giulia, Sgambato Alessandro

Abstract excerpt

Liquid biopsy has become a useful alternative in metastatic colorectal cancer (mCRC) patients when tissue biopsy of metastatic sites is not feasible. In this study we aimed to investigate the clinical utility of circulating exosomes DNA in the management of mCRC patients. Exosomes level and KRAS mutational status in exosomal DNA was assesed in 70 mCRC patients and 29 CRC primary tumor and were analysed at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA
Share to Colonic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exosomes

Share to Kaplan-Meier Estimate

Share to Liquid Biopsy

Share to Progression-Free Survival

Share to Proto-Oncogene Proteins p21(ras)

Share to Rectal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34811396
DOI: 10.1038/s41598-021-01668-7
PMCID: PMC8608842

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer.PMID 34811396Read ↗

Performance of KRAS mutation detection in plasma exosomes from patients with early-stage colorectal cancer.Semantic proximity Read ↗

Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA.Semantic proximity Read ↗

KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.Semantic proximity Read ↗

Urinary measurement of circulating tumor DNA for treatment monitoring and prognosis of metastatic colorectal cancer patients.Semantic proximity Read ↗

RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.Semantic proximity Read ↗

Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach.Semantic proximity Read ↗

Current and Emerging Biomarkers in Metastatic Colorectal CancerSemantic proximity Read ↗

Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer.Semantic proximity Read ↗

Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.Semantic proximity Read ↗

Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancerSemantic proximity Read ↗

Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.Semantic proximity Read ↗

Colorectal cancer-derived exosomes and modulation KRAS signaling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.